NUERODIAGNOSTIC INSTITUTE — History
CCN 154008 | 3-year financial timeline | COVID resilience: 83/100
🛡️ Public data only — no PHI permitted on this instance.
$29M
Latest Revenue (FY2022)
+31.1%
Revenue CAGR (3yr)
-38.2%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $17M | $10M | $29M | +183.6% | +31.1% |
| Operating Expenses | $30M | $32M | $40M | +27.9% | +15.2% |
| Operating Margin | -79.0% | -100.0% | -38.2% | +61.8% | +0.0% |
| Net Income | $-13M | $-21M | $-11M | +47.5% | +0.0% |
| Licensed Beds | 159 | 159 | 159 | +0.0% | +0.0% |
| Total Patient Days | 20,558 | 24,273 | 26,230 | +8.1% | +13.0% |
| Medicare Day % | nan% | 0% | nan% | +nan% | +nan% |
| Medicaid Day % | 38% | 36% | 40% | +10.1% | +2.2% |
COVID Impact & Recovery
Resilience Score: 83/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +72.0% ($17M → $29M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▶ Stable
vs State Average ()
Revenue Growth
+31.1%
This Hospital
+7.6%
State Avg
Latest Margin
-38.2%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $35M | -17.7% |
| FY2024 (proj) | $42M | 2.7% |
| FY2025 (proj) | $48M | 23.2% |